Related by context. All words. (Click for frequent words.) 68 tumors 65 glioblastoma 65 neuroendocrine tumors 65 medulloblastoma 65 lung tumors 64 metastases 64 GISTs 63 pancreatic tumors 63 Glioblastoma 63 grade gliomas 63 metastatic disease 63 prostate cancers 62 malignancy 62 GBM tumors 62 metastatic lesions 62 Median survival 62 breast tumors 62 seminoma 62 gliomas 61 malignant gliomas 61 anaplastic 61 metastatic tumors 61 pancreatic cancers 61 carcinoid 61 metastatic cancer 61 neuroblastomas 61 follicular lymphoma 61 lymphomas 61 metastasis 60 BRAF gene 60 bladder cancers 60 sarcomas 60 liver metastases 60 NSCLC 60 medulloblastomas 60 gastrointestinal stromal tumors 60 Gliomas 60 osteosarcomas 60 ovarian tumors 60 gastric cancers 59 differentiated thyroid 59 tumor 59 melanomas 59 malignancies 59 seminomas 59 cancers 59 lung cancers 59 pancreatic adenocarcinoma 59 GIST tumors 59 epithelial tumors 59 pancreatic NET 59 Tumors 58 glioblastoma tumors 58 Glioblastoma multiforme GBM 58 Metastatic 58 tumor recurrence 58 soft tissue sarcomas 58 squamous cell 58 Follicular lymphoma 58 melanoma 58 breast carcinomas 58 brain metastases 58 prostate tumor 58 synovial sarcoma 58 hepatocellular carcinoma 58 carcinoid tumors 58 melanoma tumors 58 ependymomas 58 prostate tumors 58 Glioblastoma multiforme 58 pleural mesothelioma 58 metastatic melanoma 58 ependymoma 58 squamous cell carcinomas 58 glioblastoma multiforme GBM 58 renal tumors 57 adenocarcinoma 57 astrocytoma 57 adenocarcinomas 57 tyrosine kinase inhibitors 57 FLT3 57 EGFR mutations 57 metastatic RCC 57 imatinib Gleevec 57 basal cell carcinomas 57 distant metastases 57 metastatic prostate cancer 57 Basal cell 57 breast cancers 57 EGFRvIII 57 complete cytogenetic 57 carcinoma 57 metastatic melanomas 57 malignant pleural mesothelioma 57 metastatic cancers 57 mesotheliomas 57 CLL cells 57 preoperative chemotherapy 57 leukemias 57 myeloma cells 57 serous ovarian cancer 57 indolent lymphomas 57 meningiomas 57 astrocytomas 57 Sarcomas 57 imatinib 57 PKCi 57 Glioma 57 acute leukemias 56 WT1 56 solid tumors 56 distant metastasis 56 Gleevec resistant 56 cell lymphomas 56 PSADT 56 Carcinoid tumors 56 prostate adenocarcinoma 56 carcinomas 56 gastrointestinal stromal tumor GIST 56 BRAF mutation 56 renal cell carcinomas 56 epithelial cancers 56 malignant tumors 56 malignant melanomas 56 lymphoma subtypes 56 neuroendocrine cancers 56 lung adenocarcinomas 56 postoperative pathology 56 tumor cells 56 papillary thyroid cancer 56 familial ALS 56 Hurthle cell 56 advanced NSCLC 56 molecularly targeted 56 brain tumor glioblastoma multiforme 56 myeloid leukemia 56 nonsmall cell lung cancer 56 grade dysplasia 56 pancreatic tumor 56 leukemia AML 56 micrometastases 56 B CLL 56 NF1 55 lung adenocarcinoma 55 HER2 positive breast cancer 55 indolent NHL 55 squamous cell cancer 55 nanomolar 55 malignant cells 55 metastatic colon cancer 55 cisplatin resistant 55 basal cell 55 HCV infection 55 squamous cell cancers 55 SOD1 55 leukaemias 55 HER2 positive 55 neoadjuvant therapy 55 aneuploid cells 55 metastatic 55 relapsing remitting 55 medullary thyroid cancer 55 Lymphomas 55 BCR ABL 55 gastrointestinal stromal tumor 55 rhabdomyosarcoma 55 neuroblastoma cells 55 renal carcinoma 55 familial pancreatic cancer 55 sarcomatoid 55 malignant lesions 55 bone metastasis 55 hematologic malignancies 55 BRAF mutations 55 hepatocellular carcinoma HCC 55 thymoma 55 cyclin E 55 EGF receptor 55 cell carcinoma 55 chemotherapeutic regimens 55 basal cell cancer 55 taxanes 55 renal cell carcinoma 55 pCR 55 Tumours 55 malignant melanoma 55 PARP inhibitors 55 metastatic kidney 55 noncancerous cells 55 premalignant 55 esophageal adenocarcinoma 55 myeloproliferative disorders 55 standard chemotherapy regimens 55 adenoma 55 prostate tissue 55 myelofibrosis polycythemia vera 55 tumor shrinkage 55 TACE 54 MMP inhibitors 54 pulmonary metastases 54 neoplasms 54 Malignant melanoma 54 hematopoietic cells 54 AMN# [001] 54 lung metastases 54 locoregional recurrence 54 Bcr Abl 54 glioblastoma multiforme 54 metastatic lung cancer 54 advanced adenomas 54 EGFR mutation 54 DLBCL 54 Squamous 54 topotecan 54 malignant growths 54 molecular abnormalities 54 myelodysplastic syndrome MDS 54 uveal melanoma 54 candidemia 54 cytoreduction 54 EGFR 54 histologies 54 squamous 54 basal cell carcinoma BCC 54 carcinoid cancer 54 leukemic cells 54 lung nodules 54 colorectal liver metastases 54 neoadjuvant chemotherapy 54 EGFr 54 MALT lymphoma 54 neoplasm 54 Hepatocellular Carcinoma HCC 54 p# mutations 54 malignant pheochromocytoma 54 sarcoma 54 mesenchymal cells 54 Leukemias 54 brain tumors 54 gefitinib 54 biochemical recurrence 54 Glioblastomas 54 oncogenes 54 CMV disease 54 T#I [002] 54 premalignant lesions 54 cytogenetic responses 54 metastasise 54 EGFR protein 54 chemotherapeutic agents 54 endometrial cancers 54 prostate carcinoma 54 medically inoperable 54 endostatin 54 curable cancers 54 HER2 positive tumors 54 invasive ductal 54 recurrent glioblastoma multiforme GBM 54 HNSCC 54 nonmelanoma skin cancers 54 nasopharyngeal carcinoma 54 microRNA miR 54 follicular lymphomas 54 glioma 54 Metastatic melanoma 54 HER2 positive cancers 54 gefitinib Iressa 54 leukemia ALL 54 benign tumors 54 meningioma 54 oligodendrogliomas 53 chemoradiation 53 ADPKD 53 lymphoma 53 genetic alterations 53 grade glioma 53 IGF 1R 53 papillary renal cell carcinoma 53 cancerous cells 53 K ras 53 alveolar rhabdomyosarcoma 53 mesothelin 53 neoplasia 53 glioblastoma cells 53 DCIS 53 thymic carcinoma 53 T#I mutant 53 liver metastasis 53 indolent lymphoma 53 Meningiomas 53 MGUS 53 Recurrences 53 childhood leukemias 53 acute myelogenous leukemia AML 53 Malignant tumors 53 colon cancers 53 KRAS wild 53 ruptured aneurysms 53 Rectal cancer 53 bowel cancers 53 anthracyclines 53 CLL 53 metastatic renal cell carcinoma 53 Burkitt lymphoma 53 Metastasis 53 Papillary 53 pituitary adenomas 53 chemotherapies 53 bleomycin 53 Gefitinib 53 grade cervical intraepithelial 53 gastric carcinoma 53 melanoma lesions 53 ovarian cancers 53 lymph node metastases 53 papillary carcinoma 53 MYCN amplification 53 nasopharyngeal cancer 53 Anthracycline 53 squamous cell carcinoma SCC 53 adenomas 53 prostate cancer PCa 53 hepatocellular carcinomas 53 interferon 53 Esophageal cancer 53 BRCA mutations 53 B7 H3 53 benign polyps 53 paragangliomas 53 tumor regression 53 hyperoxaluria 53 TKIs 53 EoE 53 Glioblastoma Multiforme 53 precancerous spots 53 essential thrombocythemia 53 bronchogenic carcinoma 53 chronic lymphocytic leukemia CLL 53 hematological cancers 53 locoregional 53 TTR gene 53 mutated KRAS 53 dasatinib 53 teratoma 53 GBMs 53 Melanomas 53 colorectal carcinoma 53 vinca alkaloids 52 imatinib therapy 52 Malignant mesothelioma 52 chemotherapy regimens 52 basal cell nevus syndrome 52 lymphoid cells 52 KRAS gene 52 anticancer drugs 52 angiosarcoma 52 PLX# 52 prostate cancer CaP 52 GRP# 52 peritoneal carcinomatosis 52 Imatinib 52 cell lung cancer 52 anaplastic lymphoma kinase 52 ccRCC 52 hamartomas 52 PCa 52 basal cell cancers 52 colorectal tumors 52 node metastases 52 ovarian lung 52 lung metastasis 52 CMV infection 52 genetic alteration 52 cranial radiation 52 heavily pretreated 52 xenograft tumors 52 tumor progression 52 thyroid nodules 52 ductal breast cancer 52 gene amplification 52 DMARDs 52 myocytes 52 oncoprotein 52 HER2 52 recurrent GBM 52 papillary 52 MDM2 52 epithelial tissues 52 underwent resection 52 Cholangiocarcinoma 52 nodular melanoma 52 neuroblastoma 52 anti angiogenic drugs 52 atypical hyperplasia 52 oncoproteins 52 EGFR inhibitors 52 hormonal therapies 52 colorectal cancers 52 Testicular cancer 52 precursor lesions 52 ansamycin 52 mycosis fungoides 52 lobular cancer 52 neuroblastoma tumors 52 pancreatic carcinoma 52 axillary lymph nodes 52 cisplatin 52 neurofibromas 52 cytogenetic response 52 adenomatous polyps 52 breast cancer subtypes 52 breast irradiation 52 Glioblastoma Multiforme GBM 52 cutaneous squamous cell carcinoma 52 skeletal metastases 52 cell lymphoma CTCL 52 lymphocytic 52 frontotemporal dementia 52 Pancreatic NET 52 histologic subtype 52 basal cells 52 Stat5 52 sentinel nodes 52 Polyps 52 cystectomy 52 castrate resistant 52 STAT3 52 mtDNA mutations 52 molecular subtypes 52 ALK mutations 52 HCV infections 52 epithelioid 52 tyrosine kinase inhibitors TKIs 52 adjuvant radiation 52 radiochemotherapy 52 steatohepatitis 52 K ras mutations 52 cytoreductive surgery 52 lobular carcinoma 52 radiation therapy SBRT 52 APOL1 52 paroxysmal AF 52 subependymal giant cell 52 carcinoid tumor 52 sporadic ALS 52 liposarcoma 52 SUVmax 52 Pleural mesothelioma 52 nilotinib 52 HSCT 51 pilocytic astrocytomas 51 Carcinoma 51 tumor suppressor genes 51 mutant p# 51 complete remissions 51 diabetic nephropathy 51 chronic myelogenous leukemia CML 51 TGF beta signaling 51 malignant nodules 51 KRAS 51 recurrent glioblastoma multiforme 51 sarcosine 51 mutations 51 Brain metastases 51 cell carcinomas 51 malignant neoplasms 51 metastatic colorectal cancer 51 idiopathic myelofibrosis 51 thyroglobulin 51 mammary cells 51 indolent tumors 51 Pancreatic neuroendocrine tumors 51 breast carcinoma 51 cervical lesions 51 anti angiogenic therapy 51 oligodendroglioma 51 lymph node involvement 51 disease progression 51 PCNSL 51 refractory CML 51 myeloproliferative diseases 51 complete cytogenetic response 51 paraganglioma 51 FTLD 51 lymphatic tissue 51 heavily pretreated patients 51 glial tumors 51 cutaneous melanoma 51 sentinel node 51 hormone deprivation 51 metastatic malignant melanoma 51 leukaemic stem cells 51 androgen deprivation 51 Epstein Barr virus EBV 51 EGFR TKI 51 metastatic GIST 51 mTOR inhibitors 51 chemotherapeutic drugs 51 colon carcinoma 51 commonly mutated genes 51 thyroid cancers 51 mutant protein 51 Crizotinib 51 superficial bladder cancer 51 chronic lymphocytic leukemia 51 retinoblastoma 51 myeloid cells 51 CDK4 51 colorectal cancer 51 underwent surgical resection 51 non Hodgkin lymphomas 51 BRAF protein 51 Chronic lymphocytic leukemia 51 NF kB pathway 51 esophageal tumors 51 HCV infected 51 FOLFOX4 51 malignant brain 51 osteopontin 51 grade serous ovarian 51 Apoptosis 51 systemic scleroderma 51 decitabine 51 hematopoietic cell 51 bladder tumors 51 HbF 51 unmutated 51 fibroadenomas 51 Pancreatic cancer 51 EpCAM 51 lymphocytic leukemia 51 CYT# potent vascular disrupting 51 chromosomal aberrations 51 SATB1 51 ductal cancer 51 Acoustic neuromas 51 colon tumors 51 herpesviruses 51 neural cells 51 TP# mutation 51 MSH2 51 GRNOPC1 cells 51 operable breast cancer 51 NKX2 51 cancerous tumors 51 xenograft models 51 testicular cancers 51 hypermethylation 51 adjuvant therapy 51 resectable 51 CaP 51 alkylating agents 51 VZV 51 axillary dissection 51 Barrett esophagus 51 recurrent NSCLC 51 pathogenic viruses 51 leiomyosarcoma 51 malignant lymphomas 51 Squamous cell 51 DIPG 51 Dr. Victor Velculescu 51 hedgehog pathway 51 radiofrequency ablation RFA 51 chronic GVHD 51 pluripotent cells 51 anaplastic thyroid cancer 51 interferon alfa 51 elevated CRP 51 TMEM#B 51 blastomeres 51 stage IIIB IV 51 embryonal rhabdomyosarcoma 51 ADAM# 51 Hedgehog pathway 51 p# mutation 51 KIT mutations 51 Anaplastic 51 EGFR tyrosine kinase inhibitors 51 skin cancers 51 taxane chemotherapy 51 idarubicin 51 Metastases 51 untreated metastatic melanoma 51 radiosensitive 51 prostate pancreatic 51 noninvasive imaging 51 azacitidine 51 KRAS oncogene 51 hepatitis C genotype 51 HAAH 51 neoplastic cells 51 multiple myeloma 51 squamous cell carcinoma 51 PTLD 51 chemo resistant 51 noncoding RNAs 51 transgene expression 51 Wilms tumor 51 IDH1 mutation 51 lymph nodes 51 sorafenib 51 myeloablative 51 graft dysfunction 51 taxane therapy 51 basal cell carcinoma 51 cancer metastasizes 51 leukemia CLL 51 Alemtuzumab 51 metastatic colorectal 51 GSTP1 51 squamous cell skin 51 castration resistant prostate cancer 51 flavopiridol 51 Mesenchymal 51 biliary strictures 51 Cell Lung Cancer 50 ErbB2 positive 50 malignant lymphoma 50 Metastatic breast cancer 50 miR #b [001] 50 chromosomal rearrangement 50 Radiofrequency ablation 50 malignant neoplasm 50 hepatocellular cancer 50 GIST 50 TAp# 50 cytotoxic agents 50 adenomatous 50 Smac mimetic 50 primary biliary cirrhosis 50 Chronic myeloid leukemia CML 50 mRCC 50 HER2 overexpression 50 mammary tumors 50 TTR amyloidosis 50 inoperable tumors 50 chemotherapy regimen 50 pheochromocytoma 50 biliary tract cancer 50 temozolomide 50 MAGE A3 50 genomic alterations 50 Belldegrun 50 alanine aminotransferase ALT 50 pilocytic astrocytoma 50 immunohistochemical staining 50 metastatic renal cell 50 HDAC inhibitors 50 radical nephrectomy 50 V#F mutation 50 glioma tumors 50 metastatic bladder 50 leukemia APL 50 transarterial chemoembolization 50 MAPCs 50 pleomorphic 50 lymphoblastic leukemia 50 JMML 50 P. aeruginosa 50 Follicular Lymphoma 50 lobular breast cancer 50 Severe sepsis 50 c MET 50 histological subtype 50 Acute Myelogenous Leukemia 50 cetuximab 50 Basal cell carcinoma 50 pancreatic neuroendocrine 50 Chronic lymphocytic leukemia CLL 50 Glucocorticoids 50 JAK inhibitors 50 PC3 cells 50 PNET 50 thyroid tumors 50 chlorambucil 50 EUS FNA 50 breast lesions 50 allogeneic stem cell 50 gastric adenocarcinoma 50 CYP#C# [001] 50 acute myeloid leukemia AML 50 pancreatic neuroendocrine tumors 50 SBRT 50 sustained virologic response 50 carbohydrate antigens 50 clusterin 50 ovarian breast 50 progressive neurodegenerative disorder 50 androgen receptor AR 50 brain tumor glioblastoma 50 lymphoproliferative disorders 50 KRAS mutation 50 KRAS mutations 50 MRSA strains 50 mycophenolate mofetil 50 hepatoma 50 leukemias lymphomas 50 Candida infections 50 conventional IMRT 50 telomere lengths 50 metastatic neuroendocrine tumors 50 factor receptor EGFR 50 B7 H1 50 chemotherapeutic agent 50 NFkB 50 hyperplastic 50 rituximab 50 progranulin 50 IGFBP 3 50 AAV2 50 transplantation HSCT 50 GNAQ 50 bone metastases 50 bendamustine 50 Trastuzumab 50 lung cancer NSCLC 50 primitive neuroectodermal tumor 50 TNF antagonist 50 cholangiocarcinoma 50 gastrointestinal GI cancers 50 colorectal cancer CRC 50 schwannomas 50 IDH2 50 gastric cancer 50 S. aureus infections 50 castration resistant 50 Alessandro Riva 50 metastatic tumor 50 salinomycin 50 sirolimus 50 Malignant gliomas 50 Kufs disease 50 cell lymphoma 50 cancer mCRC 50 prostate carcinomas 50 proto oncogene 50 proteasome inhibitors 50 dacarbazine 50 malignant transformation 50 TET2 50 MUC1 50 transfected cells 50 papillary thyroid carcinoma 50 GVHD 50 osteoclast activity 50 metastatic gastric 50 FDG uptake 50 HER2 expression 50 lymphocytosis 50 Chronic Myeloid Leukemia 50 HER2/neu 50 endocrine therapies 50 myelomas 50 HGS ETR1 50 myeloproliferative neoplasms 50 lysosomal storage diseases 50 prostate epithelial cells 50 colorectal polyp 50 plexiform neurofibromas 50 BMPR2 50 glioma cells 50 medulloblastoma tumors 50 non squamous NSCLC 50 nonsense mutations 50 telomerase inhibition 50 mononuclear cells 50 chronic myeloid leukemia CML 50 cytotoxic therapies 50 Ewing sarcoma 50 lymph node dissection 50 cytologically confirmed 50 tumors GIST 50 lupus nephritis 50 leukemic blasts 50 malignant pancreatic 50 chemoradiotherapy 50 Toxicities 50 biopsies 50 olaparib 50 squamous cells 50 Acute myeloid leukemia 50 thoracoscopic lobectomy 50 multiforme 50 dyskeratosis congenita 50 microRNAs 50 interferon alpha 50 granulomas 50 nonmelanoma skin cancer 50 CD# + [001] 50 recurrent glioblastoma 50 mycobacterium 50 pneumococci 50 histologically 50 histone deacetylase inhibitors 50 congenital brain tumor 50 Peutz Jeghers syndrome 50 myelofibrosis 50 amyloid deposition 50 Acute lymphoblastic leukemia 50 hematologic toxicity 50 PARP inhibition 50 bacterial strains 50 lymph node metastasis 50 micro RNAs 50 genomic instability 50 nucleoside analogues 50 cisplatin chemotherapy 50 unspecialized cells 50 overexpress 50 radiolabeled antibodies 50 calcineurin 50 ptau 50 biochemical relapse 50 chondrocytes 50 spontaneous remission 50 refractory NSCLC 50 lipomas 50 adrenocortical carcinoma 50 LRRK2 50 GPNMB 50 carcinoids 49 vestibular schwannomas 49 chromosome aberrations 49 prostate cancer CRPC 49 Bortezomib 49 methicillin 49 receptor tyrosine kinase inhibitor 49 Mantle Cell Lymphoma 49 keloid 49 stereotactic radiosurgery 49 Malignant Melanoma 49 sulfasalazine 49 explants 49 EGFR receptor 49 Tumor cells 49 papillomas 49 neoplastic 49 aortic dissections 49 cT3 prostate cancer 49 virotherapy 49 MLL AF9 49 Omacetaxine 49 allogeneic transplants 49 metachronous 49 DFMO 49 urothelial cancer 49 low expressors 49 fibrosis 49 invasive bladder 49 adenomatous polyp 49 colorectal neoplasms 49 utrophin 49 immunocompromised mice 49 histological subtypes 49 docetaxel chemotherapy 49 radiation therapy 49 malignant glioma 49 TGF β 49 Gastric cancer 49 sCJD 49 neovascularization 49 polyps 49 multidrug resistance 49 HCV replication 49 cytotoxic chemotherapy 49 CIN3 49 axillary lymph node dissection 49 TGFBR1 * 6A 49 Wegener granulomatosis 49 ErbB2 49 clinically localized prostate 49 BRAF inhibitor 49 Cutaneous T 49 lymph tissue 49 glioblastoma multiforme tumors 49 colorectal carcinomas 49 Medulloblastoma 49 malignant mesothelioma 49 Response Evaluation Criteria 49 basiliximab 49 BRCA deficient 49 Waldenstrom macroglobulinemia 49 subtype 49 CD# mAb 49 Circulating tumor cells 49 RET PTC rearrangements 49 panobinostat 49 refractory chronic myeloid 49 FOLFIRI 49 NSCLC tumors 49 brain lesions 49 histone deacetylases 49 ocular melanoma 49 penetrance 49 inherited retinal degeneration 49 c myc 49 myeloid 49 xenografts 49 c MYC 49 IGFBP 49 lymphoid tumors 49 NKT cells 49 parthenolide 49 CIN3 + 49 HDAC 49 MEK inhibitors 49 Non Hodgkin lymphoma 49 pheochromocytomas 49 malignant fibrous histiocytoma 49 NAFLD 49 tumor xenograft models 49 squamous cell lung cancer 49 glioblastoma tumor 49 Renal cell carcinoma 49 activating mutations 49 ES cells 49 ependymal cells 49 ARVD 49 HRPC 49 leukemic stem cells 49 completely resected 49 allogeneic SCT 49 severe sepsis 49 Irinotecan 49 BMP4 49 cells hESCs 49 papillary RCC 49 EGFR gene 49 Smad3 49 atherosclerotic lesions 49 infarcts 49 anticancer agents 49 hematological malignancy 49 B lymphocytes 49 chromosomal mutations 49 asymptomatic carotid stenosis 49 HGPIN 49 nonmetastatic 49 caveolin 1 49 PNH patients 49 proliferative disorders 49 ERBB2 49 daunorubicin 49 mCRC patients 49 nucleoside analogs 49 IV NSCLC 49 hepatic metastases 49 CXCR4 49 HER2 positive metastatic breast 49 kidney urologic 49 Akt1 49 contralateral breast 49 Radiation therapy 49 tumor necrosis 49 Velculescu 49 allogeneic HSCT 49 erlotinib Tarceva ® 49 sPLA2 49 gemcitabine chemotherapy 49 hormone refractory 49 Amrubicin 49 S#A# [002] 49 adjuvant therapies 49 Doxil ® 49 Cotara 49 TKI therapy 49 leukoencephalopathy 49 Epidermal Growth Factor Receptor 49 JAK2 49 Stomach cancer 49 acute leukemia 49 KRAS mutations occur 49 carboplatin paclitaxel 49 Synovial sarcoma 49 chemoembolization 49 micrometastasis 49 DMARD 49 lung carcinomas 49 inherited mutations 49 mutated genes 49 tumor resection 49 bevacizumab Avastin ® 49 miRNAs 49 PI3K inhibitors 49 cancerous tissue 49 orthotopic model 49 telomeres shorten 49 oral squamous cell 49 uPA 49 varices 49 muscular dystrophies 49 Fludara 49 familial amyloidotic polyneuropathy FAP 49 HCV SPRINT 49 pegfilgrastim 49 mutational status 49 Novartis Gleevec 49 imatinib resistant